Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Infinis, it appears the looking glass was used before February 21 to pivot away from the U.K. to Europe. From the RNS;
‘On the basis of these excellent initial data, the Company will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year.‘
.
The length of time that HUA is taking is of course ridiculous. But none of us really know the volumes they’re selling currently. I suspect we will get at least a mildly pleasant surprise in March when they announce their FY results. And by then, although we won’t have any firm results for AVA6000 yet, I do think the deafening silence will continue, as we have had no bad news yet. All to look forward to - jam tomorrow etc. But I do think they’re going firmly in the right direction, and I’ll be very happy to hold meantime. I think it’ll be H2 next year before they’re north of £2 again, though.
£ 25.00 share price brought forward some interesting discussions.
Wednesday tomorrow. A positive RNS could set us on the way, ..
Wisheyedbortum: agree wholeheartedly. Have been in a similar length of time though haven't had the pleasure of meeting Dr. Smith. LFT seems a distraction and market discounted it not happening. AVA6k more exciting imho, can't sound too enthusiastic though in case Wyndrum accuses of ramping lol.
On testing and at risk of boring folk lets be clear Avacta has a test that is as Sensative as it can be across the infectious range and in terms of the identification of infection is as good as PCR and a damn site cheaper. There could be world wide demand for Avactas LFT and/or manufacturing partnerships. All is not lost by a longshot. All in my own opinion of course but based on available inputs.
I really don't understand why Avacta did not run through the Porton Down testing regime (including the process of freezing the samples) prior to test. I think most researchers would have been prudent enough to test their new baby with rhePorton Down methodology. If they had done that, then they would have been in a very much better place now..
I find it unbelievably arogant that they did not...
I am currently well under and waiting for lift off..
I am hoping to top up before lift off... but the silence from Avacta about contracts, sales etc is deafening..
Dr Smith may well blind us all with science but he’s also blinded many with his LFT pitches over the last year & a half.
I had shares (not many) when Avacta consolidated & added considerably more since initial news of the LFT.
Happy with progress in many respects but the guidance over the last 18 months has been beyond shambolic.
Wishey,
when you say "...and I think that the side show of LFTs is nothing worth getting screwed up about." Medusa might have a differing opinion having lumped in £20m to manufacture a test they seem unable to sell.
Accept of course it was important, had (if only), the test came out as predicted late last year then AVCt could have maybe a £b or two in its accounts and the SP could already be north of £10 or perhaps a lot more.
That money is never coming back. Its gone forever. If the test comes out tomorrow and sells in great numbers, those missed months income are already what might have been.
So I don't agree it was a side show.
However I agree that being rude to AS is completely unnecessary and well..... rude.
The point is that if Avacta hits £5 from here then the ingredients are all there for £25, you will have seen MM analysis which in my mind is solid. So top slice at £5 if you like but dont give up on the £25 if you can afford to wait a little!
No, I have been following and investing in Avacta since 2009.
When you say "been with avacta" do you work for them?
lft has only been a sideshow so far because Porton Downs ridiculous system slowed us down, then the Govmt wouldn't buy presumably on the premise it hadn't passed Porton Down and then they stopped us even selling the test in UK in order to run us through some new hoops at their own leisurely pace. Had As had a looking glass in autumn 2020 he would have pivoted abroad there and then and things would have gone a fair bit better. In any event it will still contribute materially to avct coffers over the next period of years as will other affidx diagnostic tests
I've been with Avacta since 2009. I hold 50k shares and have met Alastair on a number of occasions and disagree with the flak that he has received over the months, especially the use of "Smith" as an address. If you sat in front of him and called him "Smith" he would bury you with the technology and knowledge stored up in his incredible brain and he would make a complete fool of you. I have full confidence in the future of Avacta, and I think that the side show of LFTs is nothing worth getting screwed up about. I would also like to see £5 per share as a starter, but I'm pretty sure that the company will get bought out at some point for telephone numbers. If not, £5 per share will do me as I am knocking on a bit.
I'd suggest many would sit tight waiting for somewhere between a still undervalued £5 p/share and a fingers crossed £25
I for one would be taking some around £10 p/share and enjoying life instead of hoping for pots of gold
Timster....Avacta know exactly how it's going. IND would not have been granted if there was any doubt.
And don't forget Nasdaq. I still believe Dr Mark Goldberg was appointed to facilitate that listing.
No proof of course but the man was persuaded by something and it wasn't the colour of AS's eyes.
I don't know why i would be fuming Tim, particularly as I hold for the successful outcome of the AVA6k trial. But as usual don't let what I say get in the way of a false image you wish to perpetuate. (Although quite why is another question).
YES here we go £25 a share lol (wyn will be fuming at this thread)
Agree with BITL if AVA6000 succeeds there will be a massive rerate as it opens up the PRECISION piepline for other toxic chemotherapy pro drugs. I guess come the middle/end of next year they will have a very good idea of how the AVA6000 trial is going with the early data available Q1 next year
The strange thing is I felt we were still way undervalued at the all time high. I still wouldn't be selling at those levels as there is even more going for it now.
@beinthelead
As a long term holder, I would love to see £ 25.00 per share.
Market Cap at £ 6.25 Billion possible.
Just don't see it for a long time yet, (IMO).
As ever DYOR :-)
That’s how I see it too BITL.
With respect, Avacta’s next growth phase will be tangible, not driven by sentiment and rumour as what drove us past £2.90. Not selling at this stage was a the biggest/riskiest hedge most holders have made to date. No government contract or sales in line with AS’s ramps promoted the fall.
Avacta’s next significant move north will be on the back of AVA, which will be valued way more than £1.65bn.
In summary, £25 is achievable on a successful AVA.
I am a long term holder and have confidence in Avacta.
Current market cap = £ 275m. 50,000 shares currently worth £ 55,000.
When we get back to previous high of £ 2.91, 50,000 shares worth £ 145,500 and most/all investors back in the black, (+ve)
50,000 shares at £ 5.00 would be £ 250,000 and brilliant. Avacta market cap would be a realistic £ 1.25 billion. (++ve)
£ 25.00 per share sounds wonderful but let’s be realistic. Market Cap at £ 6.25 Billion. Not for a long time, (IMO)
If you are holding 50,000 shares and the share price hit £ 5.00,
would you really sit tight in the hope of £ 25.00 per share = £ 1,250,000?
There will be a number of long term holders who regret not top slicing when we were at £ 2.91.
Love the enthusiasm, but let’s be realistic and not too greedy, …. IMO
Still say Avacta is a Buy at current levels.
As ever DYOR :-)